NIH funds research on pan-coronavirus vaccines
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today awarded grants to Brigham and Women’s Hospital and two universities to research and develop vaccine candidates that provide broad protective immunity to multiple coronavirus strains.
“These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential,” said NIAID Director Anthony Fauci, M.D.
The Pan-Coronavirus Vaccine Development Program expects to award additional grants to projects in 2022.
Related News Articles
Headline
Former AHA Board Member John “Jack” J. Lynch III and AHA President and CEO Rick Pollack have been announced as the 2026 recipients of the American College of…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The National Emerging Special Pathogens Training and Education Center announced Oct. 15 that it will award $37.5 million in grants to 75 hospitals seeking to…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The AHA’s Society for Health Care Strategy & Market Development Aug. 21 announced Donna Teach, chief marketing and communications officer for Nationwide…
Perspective
The job description for the ideal health care leader in coming years might read something like this:Wanted: Bold, compassionate innovator who unites clinical…